Your SlideShare is downloading. ×
Hormone refractory breast cancer – pipeline review, h2 2012
Hormone refractory breast cancer – pipeline review, h2 2012
Hormone refractory breast cancer – pipeline review, h2 2012
Hormone refractory breast cancer – pipeline review, h2 2012
Hormone refractory breast cancer – pipeline review, h2 2012
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Hormone refractory breast cancer – pipeline review, h2 2012

262

Published on

2012 || Oncology || Hormone Refractory Breast Cancer – Pipeline Review, H2 2012 || Aarkstore.com

2012 || Oncology || Hormone Refractory Breast Cancer – Pipeline Review, H2 2012 || Aarkstore.com

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
262
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Aarkstore.com announces, The Latest market research report is available inits vast collection:Hormone Refractory Breast Cancer – Pipeline Review, H22012http://www.aarkstore.com/reports/Hormone-Refractory-Breast-Cancer-Pipeline-Review-H2-2012-220601.htmlRSS link of Global Markets Directhttp://www.aarkstore.com/feeds/Global-Markets-Direct.xmlSummaryGlobal Markets Direct’s, Hormone Refractory Breast Cancer - Pipeline Review, H22012, provides an overview of the Hormone Refractory Breast Cancer therapeuticpipeline. This report provides information on the therapeutic development forHormone Refractory Breast Cancer, complete with latest updates, and specialfeatures on late-stage and discontinued projects. It also reviews key playersinvolved in the therapeutic development for Hormone Refractory Breast Cancer.Hormone Refractory Breast Cancer - Pipeline Review, H2 2012 is built using dataand information sourced from Global Markets Direct’s proprietary databases,Company/University websites, SEC filings, investor presentations and featuredpress releases from company/university sites and industry-specific third partysources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Hormone Refractory Breast
  • 2. Cancer.- A review of the Hormone Refractory Breast Cancer products under developmentby companies and universities/research institutes based on information derivedfrom company and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.- Coverage of the Hormone Refractory Breast Cancer pipeline on the basis of route ofadministration and molecule type.- Profiles of late-stage pipeline productsTable of contents:List of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Hormone Refractory Breast Cancer Overview 6Therapeutics Development 7An Overview of Pipeline Products for Hormone Refractory Breast Cancer 7Hormone Refractory Breast Cancer Therapeutics under Development by Companies9Hormone Refractory Breast Cancer Therapeutics under Investigation byUniversities/Institutes 10Late Stage Products 11Comparative Analysis 11Mid Clinical Stage Products 12Comparative Analysis 12Pre-Clinical Stage Products 13Comparative Analysis 13Hormone Refractory Breast Cancer Therapeutics – Products under Development byCompanies 14Hormone Refractory Breast Cancer Therapeutics – Products under Investigation byUniversities/Institutes 15Companies Involved in Hormone Refractory Breast Cancer Therapeutics
  • 3. Development 16Bristol-Myers Squibb Company 16Aragon Pharmaceuticals, Inc. 17Hormone Refractory Breast Cancer – Therapeutics Assessment 18Assessment by Monotherapy Products 18Assessment by Combination Products 19Assessment by Route of Administration 20Assessment by Molecule Type 22Drug Profiles 24Fulvestrant + Lapatinib - Drug Profile 24Product Description 24Mechanism of Action 24R&D Progress 24Doxorubicin + Cyclophosphamide -List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1Cholangiocellular Hepatoma – Pipeline Review, H2 2012Hormone Refractory Breast Cancer – Pipeline Review, H2 2012Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012
  • 4. Refractory Multiple Myeloma – Pipeline Review, H2 2012Epithelial Ovarian Cancer – Pipeline Review, H2 2012Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012B-Cell Leukemia – Pipeline Review, H2 2012Malignant Neoplasms – Pipeline Review, H2 2012Recurrent Malignant Glioma – Pipeline Review, H2 2012Endobronchial Cancer – Pipeline Review, H2 2012Leiomyosarcoma – Pipeline Review, H2 2012Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012Esophageal Tumor – Pipeline Review, H2 2012Malignant Pleural Mesothelioma – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1You can also request for sample page of above mention reports onsample@aarkstore.com
  • 5. For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: enquiry@aarkstore.com

×